

Advanced Biomedical Technologies Inc.
Form 10-Q
March 17, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended January 31, 2011

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Commission file number 000-53051

Advanced BioMedical Technologies, Inc.
(Exact name of registrant as specified in its charter)

Nevada
(State or other jurisdiction of incorporation or organization)

18 Lake Ridge Drive
Middletown, NY 10940
(Address of principal executive offices, including zip code.)

(718) 766-7898
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES NO

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES NO

Edgar Filing: Advanced Biomedical Technologies Inc. - Form 10-Q

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "small reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input checked="" type="checkbox"/>

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

YES NO

As of March 11, 2011, there are 56,374,850 shares of common stock outstanding.

All references in this Report on Form 10-Q to the terms "we", "our", "us", the "Company", "ABMT" and the "Registrant" refer to Advanced BioMedical Technologies, Inc. unless the context indicates another meaning.

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

The accompanying condensed unaudited financial statements of Advanced BioMedical Technologies, Inc., formerly known as Geostar Mineral Corporation, a Nevada corporation are condensed and, therefore, do not include all disclosures normally required by accounting principles generally accepted in the United States of America. These statements should be read in conjunction with the Company's most recent annual financial statements for the year ended October 31, 2010 included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission ("SEC") on February 15, 2011. In the opinion of management, all adjustments necessary for a fair presentation have been included in the accompanying condensed financial statements and consist of only normal recurring adjustments. The results of operations presented in the accompanying condensed financial statements for the period ended January 31, 2011 are not necessarily indicative of the operating results that may be expected for the full year ending October 31, 2011.

ADVANCED BIOMEDICAL TECHNOLOGIES, INC.
AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF JANUARY 31, 2011
(UNAUDITED)

ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)

CONTENTS

	Pages
Condensed Consolidated Balance Sheets as of January 31, 2011 (unaudited) and October 31, 2010	F-1
Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended January 31, 2011 and 2010 (unaudited) and the period from inception September 25, 2002 through January 31, 2011 (unaudited)	F-2
Condensed Consolidated Statements of Stockholders' Deficiency for the period from inception September 25, 2002 through January 31, 2011 (unaudited)	F-3
Condensed Consolidated Statements of Cash Flows for the three months ended January 31, 2011 and 2010 (unaudited) and the period from inception September 25, 2002 through January 31, 2011 (unaudited)	F-4
Notes to Condensed Consolidated Financial Statements (unaudited)	F-5 – F-8

ADVANCED BIOMEDICAL TECHNOLOGIES, INC. ("ABMT")
AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
CONDENSED CONSOLIDATED BALANCE SHEETS

ASSETS

	January 31, 2011 Unaudited	October 31, 2010
CURRENT ASSETS		
Cash and cash equivalents	\$ 16,130	\$ 38,614
Other receivables and prepaid expenses	13,364	12,623
Total Current Assets	29,494	51,237
PROPERTY AND EQUIPMENT, NET	48,753	49,461
TOTAL ASSETS	\$ 78,247	\$ 100,698

LIABILITIES AND STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES		
Other payables and accrued expenses	\$ 19,559	\$ 25,711
Due to a stockholder	99,104	217,951
Due to directors	144,047	158,941
Due to a related company	405,572	400,192
Due to related parties	765,627	788,400
Total Current Liabilities	1,433,909	1,591,195

COMMITMENTS AND CONTINGENCIES	-	-
--------------------------------------	---	---

DEFICIT

ABMT Stockholders' Deficit		
Common stock, \$0.00001 par value, 100,000,000 shares authorized, 56,374,850 and 56,144,850 shares issued and outstanding as of January 31, 2011 and October 31, 2010	564	562
Common stock, 230,000 shares to be issued	-	2
Stock subscription receivable	-	(230,000)
Additional paid-in capital	1,501,391	1,494,551
Deferred stock compensation	(143,334)	(206,459)
Accumulated deficit during development stage	(2,584,318)	(2,436,044)
Accumulated other comprehensive loss	(129,965)	(113,109)
Total ABMT Stockholders' Deficit	(1,355,662)	(1,490,497)
Noncontrolling interests		
Total Deficit	(1,355,662)	(1,490,497)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	\$ 78,247	\$ 100,698

The accompanying notes are an integral part of these condensed consolidated financial statements

F-1

ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE
LOSS
(UNAUDITED)

	Three months ended		September 25, 2002 (Inception) through January 31, 2010
	2011	2010	
OPERATING EXPENSES			
General and administrative expenses	\$ 125,853	\$ 144,600	\$ 2,108,222
Depreciation	1,308	7,452	262,678
Research and development (Net of government grant)	30	1,840	119,063
Total Operating Expenses	127,191	153,892	2,489,963
LOSS FROM OPERATIONS	(127,191)	(153,892)	(2,489,963)
OTHER INCOME (EXPENSES)			
Other income	908	-	5,493
Interest income	24	13	1,625
Interest paid to a stockholder and related parties	(14,826)	(12,831)	(115,221)
Imputed interest	(6,840)	(7,388)	(183,924)
Other expenses	(349)	(293)	(19,533)
Total Other Expenses, net	(21,083)	(20,499)	(311,560)
LOSS FROM OPERATIONS BEFORE TAXES	(148,274)	(174,391)	(2,801,523)
Income tax expense	-	-	-
NET LOSS	(148,274)	(174,391)	(2,801,523)
Net loss attributable to noncontrolling interests	-	-	217,205
NET LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS	(148,274)	(174,391)	(2,584,318)
OTHER COMPREHENSIVE (LOSS) INCOME			
Total other comprehensive (loss) income	(16,856)	44	(129,965)
Add: foreign currency translation loss attributable to noncontrolling interest	-	-	-
Foreign currency translation (loss) income attributable to ABMT common stockholders	(16,856)	44	(129,965)
COMPREHENSIVE LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS	\$(165,130)	\$(174,347)	\$(2,714,283)
Net loss per share-basic and diluted	\$(0.00)	\$(0.00)	

Weighted average number of shares
outstanding during the period

- basic and diluted	56,374,850	55,732,159
---------------------	------------	------------

The accompanying notes are an integral part of these condensed consolidated financial statements

F-2

ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIENCY (UNAUDITED)

	Common Stock Number of Shares	Stock Amount	Shares to be issued Number of Shares	Stock Subscriptions Amount	receivable	Additional Paid-in capital	Deferred Stock Compensation	Accumulated deficit during Development stage	Accumulated other Comprehensive loss	Nonconforming interest
Stock issued to founders for cash	50,510,000	\$ 505	-	\$-	\$-	\$275,002	\$-	\$-	\$-	\$217
Net loss for the period	-	-	-	-	-	-	-	(40,343)	-	(17,)
Foreign currency translation loss	-	-	-	-	-	-	-	-	(225)	10
Comprehensive loss	-	-	-	-	-	-	-	-	-	-
Balance at December 31, 2003	50,510,000	505	-	-	-	275,002	-	(40,343)	(225)	199
Net loss for the year	-	-	-	-	-	-	-	(65,960)	-	(28,)
Foreign currency translation loss	-	-	-	-	-	-	-	-	(357)	2
Comprehensive loss	-	-	-	-	-	-	-	-	-	-
Balance at December 31, 2004	50,510,000	505	-	-	-	275,002	-	(106,303)	(582)	171
Imputed interest on advances from a stockholder and related company	-	-	-	-	-	23,103	-	-	-	-

Edgar Filing: Advanced Biomedical Technologies Inc. - Form 10-Q

Net loss for the year	-	-	-	-	-	-	-	(357,863)	-	(15,000)
Foreign currency translation loss	-	-	-	-	-	-	-	-	(12,290)	2,000
Comprehensive loss	-	-	-	-	-	-	-	-	-	-
Balance at December 31, 2005	50,510,000	505	-	-	-	298,105	-	(464,166)	(12,872)	20,000
Imputed interest on advances from a stockholder and related company	-	-	-	-	-	27,184	-	-	-	-
Net loss for the year	-	-	-	-	-	-	-	(172,738)	-	(18,000)
Foreign currency translation loss	-	-	-	-	-	-	-	-	(6,084)	(2,000)
Comprehensive loss	-	-	-	-	-	-	-	-	-	-
Balance at December 31, 2006	50,510,000	505	-	-	-	325,289	-	(636,904)	(18,956)	-
Imputed interest on advances from a stockholder, related company and related party	-	-	-	-	-	39,021	-	-	-	-
Net loss for the year	-	-	-	-	-	-	-	(196,871)	-	-
Foreign currency translation loss	-	-	-	-	-	-	-	-	(27,401)	-

Edgar Filing: Advanced Biomedical Technologies Inc. - Form 10-Q

Comprehensive loss	-	-	-	-	-	-	-	-	-	-
Balance at December 31, 2007	50,510,000	505	-	-	-	364,310	-	(833,775)	(46,357)	-
Imputed interest on advances from a stockholder and related company	-	-	-	-	-	27,764	-	-	-	-
Net loss for the period	-	-	-	-	-	-	-	(227,038)	-	-
Foreign currency translation loss	-	-	-	-	-	-	-	-	(35,833)	-
Comprehensive loss	-	-	-	-	-	-	-	-	-	-
Balance at October 31, 2008	50,510,000	505	-	-	-	392,074	-	(1,060,813)	(82,190)	-
Recapitalization	5,104,000	51	-	-	-	(51)	-	-	-	-
Stock issued for services (\$3.05 per share)	100,000	1	-	-	-	304,999	(292,292)	-	-	-
Stock issued for cash in private placement (\$1.15 per share)	5,000	-	-	-	-	5,750	-	-	-	-
Stock issued for cash in private placement (\$1.15 per share)	2,000	-	-	-	-	2,300	-	-	-	-
Contributed capital	-	-	-	-	-	26,950	-	-	-	-
Distributed to the stockholders	-	-	-	-	-	(31,409)	-	-	-	-

Imputed Interest on advances from a stockholder and related company	-	-	-	-	-	31,656	-	-	-	-
Net loss for the year	-	-	-	-	-	-	-	(558,432)	-	-
Foreign currency translation loss	-	-	-	-	-	-	-	-	(1,856)	-
Comprehensive loss	-	-	-	-	-	-	-	-	-	-
Balance at October 31, 2009	55,721,000	557	-	-	-	732,269	(292,292)	(1,619,245)	(84,046)	-
Stock issued for cash in private placement (\$1.5 per share)	6,667	-	-	-	-	10,000	-	-	-	-
Stock issued for cash in private placement (\$1.5 per share)	16,667	-	-	-	-	25,000	-	-	-	-
Stock issued for cash in private placement (\$1.5 per share)	136,833	2	-	-	-	205,248	-	-	-	-
Stock to be issued for cash in private placement (\$1.0 per share)	-	-	230,000	2	(230,000)	229,998	-	-	-	-
Stock issued for services (\$1 per share)	100,000	1	-	-	-	99,999	(100,000)	-	-	-
Stock issued for services (\$1 per share)	13,683	-	-	-	-	13,683	(13,683)	-	-	-

Edgar Filing: Advanced Biomedical Technologies Inc. - Form 10-Q

Stock issued for services (\$1 per share)	150,000	2	-	-	-	149,998	(150,000)	-	-	-
Amortisation for stock issued for services	-	-	-	-	-	-	349,516	-	-	-
Imputed interest on advances from a stockholder and related company	-	-	-	-	-	28,356	-	-	-	-
Net loss for the year	-	-	-	-	-	-	-	(816,799)	-	-
Foreign currency translation loss	-	-	-	-	-	-	-	-	(29,063)	-
Comprehensive loss	-	-	-	-	-	-	-	-	-	-
Balance at October 31, 2010	56,144,850	562	230,000	2	(230,000)	1,494,551	(206,459)	(2,436,044)	(113,109)	-
Stock issued for cash in private placement (\$1 per share)	230,000	2	(230,000)	(2)	230,000	-	-	-	-	-
Imputed interest on advances from a stockholder and related company	-	-	-	-	-	6,840	-	-	-	-
Amortisation for stock issued for services	-	-	-	-	-	-	63,125	-	-	-
Net loss for the period	-	-	-	-	-	-	-	(148,274)	-	-
Foreign currency translation loss	-	-	-	-	-	-	-	-	(16,856)	-

Comprehensive loss	-	-	-	-	-	-	-	-	-	-
Balance at January 31, 2011	56,374,850	\$564	-	\$-	\$-	\$1,501,391	\$(143,334)	\$(2,584,318)	\$(129,965)	\$-

The accompanying notes are an integral part of these condensed consolidated financial statements

ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

	Three months ended		September 25, 2002 (inception) through January 31, 2010
	January 31,		
	2011	2010	
CASH FLOWS FROM OPERATING ACTIVITIES			
Net loss	\$(148,274)	\$(174,391)	\$(2,584,318)
Adjustments to reconcile net loss to cash used in operating activities:			
Depreciation	1,308	7,452	262,678
Loss on disposal of fixed assets	-	-	5,327
Stock issued for services	63,125	38,125	425,350
Noncontrolling interests	-	-	(217,205)
Imputed interest	6,840	7,388	183,924
Changes in operating assets and liabilities (Increase) decrease in:			
Other receivables and prepaid expenses	(566)	-	(13,364)
Increase (decrease) in:			
Other payables and accrued expenses	(6,205)	6,114	19,559
Net cash used in operating activities	(83,772)	(115,312)	(1,918,049)
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of property and equipment	-	(4,389)	(316,759)
Due from a related party	-	-	-
Due from stockholders	-	-	-
Due from a noncontrolling stockholder of a subsidiary	-	766	-
Net cash used in investing activities	-	(3,623)	(316,759)
CASH FLOWS FROM FINANCING ACTIVITIES			
Stock issued to founders	-	-	505
Proceeds from issuance of shares	230,000	35,000	478,300
Contribution by stockholders	-	-	519,157
Distributed to stockholders	-	-	(31,409)
Due to a stockholder	(118,352)	6,560	99,104
Due to directors	(16,832)	(18,530)	144,047
Due to a related company	-	-	405,572
Due to related parties	(32,963)	114,531	765,627
Net cash provided by financing activities	61,853	137,561	2,380,903
EFFECT ON EXCHANGE RATES ON CASH	(565)	(11)	(129,965)

Edgar Filing: Advanced Biomedical Technologies Inc. - Form 10-Q

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(22,484)	18,615	16,130
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	38,614	10,606	-
CASH AND CASH EQUIVALENTS AT END OF PERIOD	\$ 16,130	\$ 29,221	\$ 16,130

The accompanying notes are an integral part of these condensed consolidated financial statements

F-4

ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)

NOTES TO THE CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS (UNAUDITED)

NOTE 1 BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, the unaudited condensed consolidated financial statements contain all adjustments consisting only of normal recurring accruals considered necessary to present fairly the Company's financial position as of January 31, 2011, the consolidated results of operations for the three months ended January 31, 2011 and 2010 and for the period from September 25, 2002 (inception) to January 31, 2011 and consolidated statements of cash flows for the three months ended January 31, 2011 and 2010 and for the period from September 25, 2002 (inception) to January 31, 2011. The consolidated results for the three months ended January 31, 2011 are not necessarily indicative of the results to be expected for the entire fiscal year ending October 31, 2011. These consolidated financial statements should be read in conjunction with the consolidated financial statements and notes for the year ended October 31, 2010 appearing in the Company's annual report on Form 10-K as filed with the Securities and Exchange Commission on February 15, 2011.

NOTE 2 ORGANIZATION

Advanced BioMedical Technologies, Inc. (fka “Geostar Mineral Corporation” or “Geostar”) (“ABMT”) was incorporated in Nevada on September 12, 2006.

Shenzhen Changhua Biomedicine Engineering Company Limited (“Shenzhen Changhua”) was incorporated in the People’s Republic of China (“PRC”) on September 25, 2002 as a limited liability company with a registered capital of \$724,017. Shenzhen Changhua is owned by two stockholders in the proportion of 70% and 30% respectively. Shenzhen Changhua plans to develop, manufacture and market self-reinforced, re-absorbable degradable PA screws, robs and binding ties for fixation on human fractured bones. The Company is currently conducting clinical trials on its products and intends to raise additional capital to produce and market its products commercially pending the approval from the State Food and Drug Administration (“SFDA”) of the PRC on its products. The Company has no revenue since its inception and, in accordance with Accounting Standards Codification (“ASC”) Topic 915, “Development Stage Entities” (formerly Statement of Financial Accounting Standard (“SFAS”) No. 7, “Accounting and Reporting by Development Stage Enterprise”), is considered a Development Stage Company.

Masterise Holdings Limited (“Masterise”) was incorporated in the British Virgin Islands on May 31, 2007 as an investment holding company and was then owned as to 63% by the spouse of Shenzhen Changhua’s 70% majority stockholder at the time and 37% by a third party corporation.

On January 29, 2008, Masterise entered into a Share Purchase Agreement (“the Agreement”) with a stockholder of Shenzhen Changhua whereupon Masterise acquired 70% of Shenzhen Changhua for US\$64,100 in cash. The acquisition was completed on February 25, 2008. As both Masterise and Shenzhen Changhua were under common control and management, the acquisition was accounted for as a reorganization of entities under common control.

Accordingly, the operations of Shenzhen Changhua for the three months ended January 31, 2011 and 2010 were included in the consolidated financial statements as if the transactions had occurred retroactively.

F-5

On December 31, 2008, ABMT consummated a Share Exchange Agreement (“the Exchange Agreement”) with the stockholders of Masterise pursuant to which ABMT issued 50,000 shares of Common Stock to the stockholders of Masterise for 100% equity interest in Masterise.

Concurrently, on December 31, 2008, a major stockholder of ABMT also consummated an Affiliate Stock Purchase Agreement (the “Affiliate Agreement”) with thirteen individuals including all the stockholders of Masterise, pursuant to which the major stockholder sold a total of 5,001,000 shares of ABMT’s common stock for a total aggregate consideration of \$5,000, including 4,438,250 shares to the stockholders of Masterise.

On consummation of the Exchange Agreement an